



# Developing Cutting-Edge Treatments for Ovarian Cancer

Ovarian cancer is the second most common gynecological cancer in the world. Often diagnosed at an advanced stage, ovarian cancer has the highest mortality rate among cancers in the female reproductive system.

In 2022, there were approximately 325,000 new cases of ovarian cancer worldwide and more than 207,000 deaths. Fortunately, progress in screening and early detection along with new breakthrough therapies offer promise for the treatment of this disease.

## Ovarian Cancer Trial Expertise

Ovarian cancer is one of Worldwide Oncology's greatest areas of expertise. Over the last five years, we have managed complex first-in-human through to large 400+ patient Phase III ovarian cancer trials across North America, Europe, and Asia-Pacific.

Clinical trial enrollment in ovarian cancer studies is challenging since ovarian cancer often presents with gastrointestinal (GI)-related symptoms and patients need to be referred to gynecologic oncology specialists by their local GI or family medicine doctor. Partnering with the right sites and cooperative groups to navigate the competitive landscape and accelerate enrollment is critical to successfully managing ovarian trials.

It is important to work with an oncology CRO that understands and can proactively navigate the operational nuances unique to these studies and patient population.



### Robust Pipeline of Ovarian Cancer Trials

- Global footprint:
  - North America, Europe, and Asia-Pacific
- Study experience:
  - Phase I to 400+ patient Phase III trials
  - Aiming to enroll 2,100+ patients
- Site experience:
  - 300 investigative sites in 13 countries
- FDA designations:
  - Fast Track
  - Accelerated Approval



### We Understand the Nuances of Ovarian Cancer Trials

- Partner with cooperative groups:
  - The Gynecologic Oncology Group (GOG) Foundation
  - European Network of Gynecological Oncological Trial Groups (ENGOT)
- Variability in response evaluation criteria (RECIST) assessments due to:
  - Peritoneal studding
  - Proper classification of ascites
- Biomarkers to assess treatment efficacy:
  - CA125g

## Exclusively Biopharma-Focused

Built to work exclusively with biopharma, our flexible processes and approach allow us to listen first, align goals, and execute with an eye toward rapid shifts when protocols amend or Breakthrough designations move a product straight from Phase I to registration.

## Seasoned Oncology Experts


With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, and Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

## A Transparent People-First Culture With Industry-Leading Retention

We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention provides program continuity, increased efficiency, and happy investigative sites.

**90%**  
corporate  
retention  
rate

## Additional Differentiators



## Active Next-Gen Oncology Experience

Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.

